Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
zynlonta save search
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta trial therapeutics
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-12-12 (Crawled : 10:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 1.0%
H: 2.97%
C: 1.98%
zynlonta trial therapeutics results
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
Published: 2023-08-30 (Crawled : 00:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 3.33%
H: 1.61%
C: -3.23%
zynlonta meeting trial therapeutics
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Published: 2023-07-24 (Crawled : 11:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -4.03%
H: 1.4%
C: -8.39%
zynlonta license review treatment biopharma application grants
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
Published: 2023-07-20 (Crawled : 20:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
zynlonta trial therapeutics
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
Published: 2023-07-11 (Crawled : 11:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -17.72%
H: 0.51%
C: -5.13%
zynlonta trial therapeutics
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Published: 2023-06-09 (Crawled : 11:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.0%
H: 5.6%
C: 0.8%
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -4.41%
zynlonta therapeutics results
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Published: 2022-12-21 (Crawled : 09:00) - prnewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 14.15%
H: 1.93%
C: -16.25%
zynlonta treatment approved
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Published: 2022-12-21 (Crawled : 09:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 14.15%
H: 1.93%
C: -16.25%
zynlonta treatment approval therapeutics
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
Published: 2022-11-02 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.21%
H: 0.0%
C: -0.14%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 1.13%
H: 0.22%
C: -7.61%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: -0.74%
H: 6.08%
C: -2.35%
igm-2323 zynlonta collaboration therapeutics agreement
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -1.29%
H: 3.35%
C: -2.23%
zynlonta treatment europe chmp therapeutics positive
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
Published: 2022-07-20 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.26%
H: 3.04%
C: 0.53%
zynlonta trial therapeutics phase 2
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -8.91%
zynlonta biopharma trial china phase 3
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
Published: 2022-07-08 (Crawled : 09:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.11%
H: 18.91%
C: 12.68%
zynlonta europe license therapeutics agreement international
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -1.55%
H: 3.94%
C: 2.23%
zynlonta trial therapeutics phase 2b
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.07%
H: 8.09%
C: 1.01%
zynlonta services therapeutics
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
Published: 2022-01-18 (Crawled : 11:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -8.09%
H: 2.66%
C: 0.06%
zynlonta license therapeutics corporation commercialization pharma
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
Published: 2021-10-29 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.24%
H: 1.01%
C: 0.66%
europe application
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.82%
H: 0.25%
C: -4.96%
phase 2 biopharma china trial t-cell
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.22%
H: 3.07%
C: 1.2%
orphan drug europe drug therapeutics designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.